Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bexmarilimab plus azacitidine in treatment-naïve higher-risk myelodysplastic syndromes
NCT07672769Phase 2Recruiting
- Sponsor
- Faron Pharmaceuticals
- Start
- Oct 2026
- Primary completion
- Nov 2027
- Countries
- 7
01
Overview
A Phase 2 trial of bexmarilimab in myelodysplastic syndrome (MDS), sponsored by Faron Pharmaceuticals. Started Oct 2026; status: recruiting.
02
Drugs
bexmarilimab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07672769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07672769.